Core Scientific, Inc. Files Amendment No. 1 to Annual Report on Form 10-K: Key Investor Highlights

Overview

Core Scientific, Inc. (NASDAQ: CORZ) has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This filing, submitted to the U.S. Securities and Exchange Commission (SEC) on March 18, 2026, follows the original 10-K filed on March 2, 2026. The amendment is primarily to attach Exhibit 97.1, which was inadvertently omitted in the original submission.

Key Points for Investors

• No Financial Changes: The amendment does not modify, amend, or update any financial or other information contained in the original filing. There are no changes to previously reported financial results or disclosures.
• Exhibit 97.1 Added: The sole purpose of this amendment is to attach Exhibit 97.1, which relates to compensation clawback policies, potentially a price-sensitive matter for shareholders, as it could affect executive compensation and recovery of incentive-based pay if restatements are required.
• No Restatement or Error Correction: The amendment confirms that the financial statements included in the filing do not reflect the correction of any errors or restatements. No recovery analysis of incentive-based compensation for executive officers was required.
• Certification Updates: Because no financial statements are included in this Amendment No. 1, certifications pursuant to Section 906 of the Sarbanes-Oxley Act are omitted. However, new certifications under Section 302 are attached due to SEC requirements for amendments.
• Regulatory Compliance: Core Scientific confirms it has filed all documents and reports required by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a court-confirmed plan, signaling ongoing compliance following its bankruptcy proceedings.
• Shareholder Information:
  • As of June 30, 2025, public float was estimated at \$4.25 billion based on a closing share price of \$17.07.
  • The company’s securities registered with Nasdaq include:
    • Common stock (CORZ)
    • Warrants exercisable for common stock at \$0.01 per share (CORZZ)
    • Warrants exercisable for common stock at \$6.81 per share (CORZW)
  • Core Scientific is classified as a Large Accelerated Filer and not an emerging growth company or small business.
• Bankruptcy Reporting: The company confirms it is currently reporting in accordance with bankruptcy proceedings, which may be price-sensitive and relevant to shareholder value.

Potential Price-Sensitive Developments

• Compensation Clawback Policy: The inclusion of Exhibit 97.1, relating to compensation clawbacks, is significant. It outlines how the company would recover incentive-based compensation from executives in the event of a restatement. While no restatements were required in this filing, the existence and enforcement of such policies can impact executive behavior and shareholder confidence, especially in light of recent regulatory focus.
• Confirmation of No Financial Changes: The explicit statement that there are no changes to financial results or disclosures provides assurance to investors, mitigating concerns of negative surprises or restatements.
• Ongoing Bankruptcy Compliance: The company’s continued reporting under bankruptcy proceedings and confirmations of compliance may be relevant to those monitoring Core Scientific’s recovery and ongoing viability.
• Market Value Disclosure: The public float of \$4.25 billion sets a benchmark for institutional investors and may impact trading activity.

Summary for Shareholders

The Amendment No. 1 is not introducing new financial information, corrections, or restatements. Its main purpose is attaching a previously omitted exhibit relating to executive compensation clawbacks. The company reiterates its compliance with regulatory filings post-bankruptcy and confirms its market capitalization and reporting status. For investors, there is no immediate financial impact or change in company fundamentals revealed in this amendment, but the addition of Exhibit 97.1 is important for governance and may affect executive compensation practices going forward.

Disclaimer

This article is based on Core Scientific, Inc.’s Amendment No. 1 to Form 10-K for the fiscal year ended December 31, 2025. It is intended for informational purposes only and does not constitute investment advice. Investors should consult the full SEC filings and their financial advisors before making any investment decisions. The information herein is accurate as of the date of publication but may be subject to change.

View Core Scientific, Inc./tx Historical chart here